Kimia Biosciences Ltd (BSE: 530313) is a New Delhi, Delhi-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹152 Cr, it ranks #2,902 by market cap among the 6,137 Indian listed companies on FinBizNet, and #61 of 86 in Medicinal Chemicals and Botanical Products. At ₹29.99 (as of 25 Oct 2026), the share price is 30.7% below its 52-week high of ₹43.28 and 29.3% above its 52-week low of ₹23.20. The share price is down 12.4% over one year and down 6.0% over three months.
| Current Price | ₹29.99 |
|---|---|
| Market Cap | ₹152 Cr |
| BSE Code | 530313 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 20 |
| Return on Equity | 53.70% |
| Return on Assets | 7.26% |
| 52-Week Range | ₹23.20 – ₹43.28 |
| 1-Year Price Change | -12.4% |
| 3-Month Price Change | -6.0% |
| Beta (1Y) | 1.49 |
| Headquarters | New Delhi, Delhi |
| Website | www.kimiabiosciences.com |
Kimia Biosciences Limited manufactures and sells active pharmaceutical ingredients (APIs) in India. The company offers and develops APIs in the categories, including gastrointestinal agent, anti-coagulant, anti-hypertensive, lipid lowering agents, vitamin, anti-histamine, anti-convulsant, central stimulant, anti-diabetic, and anti-bacterial, as well as anti-psychotic, anti-fungal, urologicals, anti-inflammatory, prokinetic agent, cholelithiasis agent, anti-asthmatic, anti-depressant, anti-acne, decongestant, and anti-virals. It exports its products. Kimia Biosciences Limited was formerly known as Laurel Organics Ltd and changed its name to Kimia Biosciences Limited January 2019. The company was incorporated in 1993 and is based in New Delhi, India.
1. Pharmaceuticals-This segment provides contract manufacturing services for latest (R&D based) and generic (regular) bulk drug intermediates for pharmaceutical companies in India.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Kimia Biosciences Ltd | ₹152 Cr | 20 | 53.70% | — | -12.4% |
Listed by market capitalisation. Ratios are shown for context only.
Kimia Biosciences Ltd is trading at ₹29.99, with a market capitalisation of ₹152 Cr.
Kimia Biosciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Kimia Biosciences Ltd has a P/E of 20 and a return on equity of 53.70%.
Kimia Biosciences Ltd is listed on the BSE under the scrip code 530313.
Kimia Biosciences Ltd's share price is down 12.4% over one year and down 6.0% over three months. Its 52-week range is ₹23.20 to ₹43.28.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.